We have discovered a novel chemical compound, (E)-3-(furan-2-yl)--(4-sulfamoylphenyl) acrylamide, that suppresses the enzymatic activities of SARS coronavirus helicase. To determine the inhibitory effect, ATP hydrolysis and double-stranded DNA unwinding assays were performed in the presence of various concentrations of the compound. Through these assays, we obtained IC values of 2.09 ± 0.30 µM (ATP hydrolysis) and 13.2 ± 0.9 µM (DNA unwinding), respectively. Moreover, we found that the compound did not have any significant cytotoxicity when 40 µM of it was used. Our results showed that the compound might be useful to be developed as an inhibitor against SARS coronavirus.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4014/jmb.1707.07073 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling the mechanism of action of a novel natural dual inhibitor of SARS-CoV-2 Mpro and PLpro with molecular dynamics simulations.
Nat Prod Bioprospect
January 2025
Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
In the twenty-first century, we have witnessed multiple coronavirus pandemics. Despite declining SARS-CoV-2 cases, continued research remains vital. We report the discovery of sydowiol B, a natural product, as a dual inhibitor of SARS-CoV-2 main protease (Mpro) and papain-like protease (PLpro).
View Article and Find Full Text PDFViral nucleic acid load in the milk of lactating mothers with COVID-19 and the prognosis of infants.
Sci Rep
January 2025
Department of Pediatrics, Children's Medical Center, The First Hospital of Jilin University, Lequn Branch, No. 3302 Jilin Road, Changchun, 130021, China.
The global spread of the novel coronavirus disease 2019, caused by SARS-CoV-2 virus, impacts individuals of all age groups, including lactating women and children. Concerns have been raised regarding the potential transmission of SARS-CoV-2 from mother to child, following the discovery of SARS-CoV-2 RNA in human milk. Therefore, this study aims to investigate whether the Omicron novel coronavirus variants are transmitted through human milk.
View Article and Find Full Text PDFUse of Remote Regulatory Assessment (RRA) for Site Evaluations during the COVID-19 Pandemic: The USFDA's Office of Study Integrity and Surveillance (OSIS) Perspective.
AAPS PharmSciTech
January 2025
OSIS, Silver Spring, Maryland, U.S.A.
Travel restrictions during the novel coronavirus, SARS-CoV-2 (COVID-19) public health emergency affected the U.S. Food and Drug Administration's (FDA) ability to conduct on-site bioavailability/bioequivalence (BA/BE) and Good Laboratory Practice (GLP) nonclinical inspections.
View Article and Find Full Text PDFCombating COVID-19 and its co-infection by Aspergillus tamarii SP73-EGY using in vitro and in silico Studies.
Sci Rep
January 2025
Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, 33 El Buhouth St, Dokki-Giza, Egypt.
The COVID-19 pandemic has caused significant mortality and morbidity for millions of people. Severe Acute Respiratory Syndrome-2 (SARS-CoV-2) virus is capable of causing severe and fatal diseases. We evaluated the antiviral properties of Aspergillus tamarii SP73-EGY isolate extract against low pathogenic coronavirus (229E), Adeno-7- and Herpes-2 viruses.
View Article and Find Full Text PDFA comparative cohort study of post-COVID-19 conditions based on physical examination records in China.
EBioMedicine
January 2025
Biomedical Big Data Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, China. Electronic address:
Background: Coronavirus disease-2019 (COVID-19), caused by SARS-CoV-2 virus infection, is characterized as a multisystem disease, potentially yielding multifaceted consequences on various organs at multiple levels. At the end of 2022, over 90% of the Chinese population was infected by SARS-CoV-2 within 35 days because of adjustments to epidemic prevention and control policies. This short-term change provides an unprecedented opportunity for comparative studies on COVID-19 infection among large populations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!